(Image via Canopy Growth Corp.)
“Puff puff, pass” might be a thing of the past.
The world’s biggest cannabis producer,
Canopy Growth Corp. (TSX: WEED, Forum) launched two new products this week -
Tweed Quickies and Ace Valley Pinners. Smaller joints in larger pack sizes of eight or 10.
Canopy Growth commissioned a study that found that traditional 0.5 gram joints are too big for many consumers to enjoy in one sitting and take too long to consume, in addition to concerns around sharing in current times. Canopy Growth leveraged this insight to develop its first two product lines – Tweed Quickies (pictured above) in 0.35 gram and Ace Valley Pinners in 0.3 gram offerings – with research indicating this was the optimal size for a quicker session that could be enjoyed on one's own or within a group setting without the need to share.
Nanaimo, BC-based licensed producer
Tilray Inc. (NASDAQ: TLRY) reported financial results for the full fiscal year and Q4 ending May 2021. Net revenue increased 25% to
$142.2 million (USD) during the fourth quarter from $113.5 million in the prior year quarter.
The increase was driven by 36% growth in net cannabis revenue to $53.7 million, which included four weeks of contribution from legacy-Tilray, a 10% decline in distribution revenue, net beverage alcohol revenue of $15.9 million following our SweetWater acquisition on November 25, 2020, and wellness revenue of $5.8 million from
Manitoba Harvest.
Net income of $33.6 million during the fourth quarter compared to net loss of $84.3 million in the prior year quarter.
Adjusted EBITDA increased 285% to $12.3 million during the fourth quarter from $3.2 million in the prior year quarter marking the ninth consecutive quarter of positive Adjusted EBITDA.
Integrated healthcare company
Empower Clinics Inc. (CSE: CBDT, Forum) is looking for a
new Chief Financial Officer to fill the shoes of current CFO Kyle Appleby, CPA, CA.
Kyle Appleby is expected to step down from his role concurrent with hiring of the new CFO, which Empower hopes will be in place by early 4Q 2021.
Datametrex AI Ltd. (TSX-V: DM, Forum) will provide COVID-19 testing for a major US network and one of the largest streaming platforms.
Datametrex continues to provide critical COVID-19 testing kits for actors, film crews, and production support staff to prevent cluster outbreaks. Film and TV production companies all support the continued use of safety protocols, especially COVID-19 testing to keep production members and actors healthy and safe while employed on sets and in production offices.
Film and TV productions In Canada are concerned about the Delta variant (B.1.617.2. variant), a hyper-contagious SARS-CoV-2 virus strain, which was first identified in India in October 2020.
Datametrex Chief Executive Officer Marshall Gunter explained
in a recent news release that the COVID-19 testing market is an important business sector for the company and the team will continue supporting the film industry with kits and now with the Delta variant of the virus being the "the fastest and fittest," according to the World Health Organization.
The fear is that an increase in Delta variant cases may well lead to a resurgence in health and safety restrictions not just in Canada, but internationally and deter global productions from filming. The World Health Organization has called this version of the virus the fastest and fittest.
This brings us to our Investor Pulse Poll question of the week. It seems most of you who responded aren't concerned about this Delta variant, but quite a few believe that it will have as big an impact on the markets as the COVID we have already grown used to / tired of.
This week, we look to the ongoing news about inflation. As the rate continues to rise, how concerned are you that your finances can keep up? Let us know your throughts by clicking the image below and check back next week for the results.
(Click the image to cast your vote.)
A provider of intelligent video solutions for public transport and smart cities,
Gatekeeper Systems Inc. (TSX-V: GSI, Forum) reported its financial results this week for the three and nine months ended May, 2021. During the quarter, the company achieved its sixth consecutive quarter of operating profit while investing approximately $0.5 million (USD) in AI development pertaining to the Company's recently launched Automatic Lane Enforcement product offering. Revenue for the nine months ended May 31, 2021, was
$12,088,139 compared to $12,584,503 for the same period in the previous year.
What the "Buzz"
Our Bullboards have up to 2 Million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get "Buzz on the Bullboards" delivered to your inbox every Thursday!
Buzz on the Bullboards | Sign Up Here
As it continues to build momentum in expanding its EV infrastructure reach,
Extreme Vehicle Battery Technologies Corp. (CSE: ACDC, Forum) signed an exclusive agreement with
Glenhalla Estates Ltd. to provide its upcoming Automall development with IoniX Pro EV Smart Chargers.
The company has signed an agreement with Glenhalla to provide the new IoniX Pro Smart Chargers throughout the Automall, with the potential to provide further energy storage solutions and other EV and ESS infrastructure enhancements as the development continues to expand. The Automall is currently configured for ten car dealerships with room for future expansion. Current minimum requirements call for two EV Smart Chargers at each dealership. The development also includes a flagship hotel, which will require a minimum of six EV Smart Chargers. Discussions with hotel operators have also included the possibility of an IoniX Pro TITAN EnergyCore storage system.
The Automall will be strategically located in Hope, British Columbia, making the most of the districts’ plans that are geared towards encouraging a greener, more sustainable future. The company is thrilled to be offering its state-of-the-art IoniX Pro Battery solutions to assist in these initiatives.
Glenhalla executive, Michael Hache said that after considerable due diligence, his team determined that EV Battery Tech was the perfect company to team up with on this development.
“
Their technology is superior to others on the market and they embody one of greenest visions of any company I have ever encountered. We are very excited about this opportunity.”
Therma Bright Inc. (TSX-V: THRM, Forum) provided an update on its
AcuVid COVID-19 Rapid Antigen Saliva Test this week as it awaits an official response from the US Food and Drug Administration Emergency Use Authorization review for its COVID-19 rapid antigen test application.
264 people were enrolled in the clinical study to secure additional real-life patient data on its AcuVid saliva test with duration of symptoms that ranged from one day to more than 10 days.
Biopharmaceutical company
Theratechnologies Inc. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboarders who have been following its developments to commercialize innovative therapies.
TH has now established an
at-the-market equity program allowing Theratechnologies to issue and sell up to $50 million (USD) common shares from treasury to the public at the company’s sole discretion and at the prevailing market price. Sales of the common shares under the ATM program will be made pursuant to the terms of a sales agreement dated July 23rd, 2021, with
Cantor Fitzgerald & Co.
Finally we have CBD biotech company
Claritas Pharmaceuticals Inc. (TSX-V:KLY, Forum) who recently brought a study led by clinicians at
Royal Brompton & Harefield NHS Foundation Trust to the attention of investors, stating that it validates the potential of the company’s proprietary nitric oxide releasing compound, R-107, as a potential therapy for coronavirus and COVID-19 infection. In the cited study, inhaled nitric oxide was seen to significantly improve oxygen levels administered in patients with severe COVID-19 pneumonia.
The study at Royal Brompton & Harefield NHS Foundation Trust was the largest of its kind worldwide. In this study, 35 Patients with COVID-19 pneumonia who were on ventilation were given inhaled nitric oxide as part of routine care when they were failing to respond to best standard treatments. This led to significant improvements in oxygen levels and improvements in ventilatory efficiency at 24 hours and for up to five days.
For previous editions of Buzz on the Bullboards:
click here.
FULL DISCLOSURE: Extreme Vehicle Technologies Corp. is a client of Stockhouse Publishing.